A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.

Pedro Luiz Serrano Uson,Jeremiah Bearss,Hani M Babiker,Mitesh Borad

Expert opinion on drug safety（2023）

引用 0|浏览4

暂无评分

摘要

Future perspectives in the treatment of FGFR2 fused cholangiocarcinoma include the evaluation of pemigatinib in previously untreated patients and possible active combinations or sequencing strategies with other drugs.

查看译文

关键词

biliary tract cancers, cholangiocarcinoma, fibroblast growth factor receptor, pemigatinib, FGFR2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要